A little more than six months ago, Cure SMA launched the Summit of Strength Virtual Webinar Series , a program designed to help support individuals and families with SMA manage the uncertainty of life in quarantine during the global COVID-19 pandemic. We have now hosted 13 Summit of Strength educational webinars and are coming to […]
Summit of Strength Virtual Webinar Series Continues Its Success! Read More »
Contributors: Dr. Mary Schroth and Dr. Robert Graham Influenza (or flu) is a serious respiratory infection, and people of any age can get it. Since 2010, the Centers for Disease Control and Prevention (CDC) estimates that influenza has resulted in between 140,000 and 810,000 hospitalizations each year and 12,000 to 61,000 deaths. There is always
Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced 6-month interim results from their clinical program for its product candidate SRK-015, a treatment being developed for spinal muscular atrophy (SMA). SRK-015 is a highly selective inhibitor of latent myostatin and
October is National Disability Employment Awareness Month, with an official theme of Increasing Access and Opportunity. Throughout the month, we have been posting stories about adults with SMA in the workforce and are pleased to share this perspective column from Spencer Cook, as seen in the latest Fall issue of Directions. Living with a disability in the
Community Spotlight: Perspectives from Spencer Cook, Registered Accessibility Specialist Read More »
October is National Disability Employment Awareness Month, with an official theme of Increasing Access and Opportunity. Throughout the month, we will be posting stories about adults with SMA in the workforce and are pleased to share this story about Kayley Shade. Kayley Shade is a 28-year-old sports fan from Hartford, S.D. She has lived with spinal muscular
Community Spotlight: Kayley Shade of Sioux Falls Storm Read More »
Through Cure SMA’s partnership with NeurologyLive, a new patient-centered article, “Early Intervention in SMA: How Access to Therapy Will Alter Disease Management As We Know It,” is now available for viewing online. This piece features an interview with Dr. Mary Schroth, Chief Medical Officer at Cure SMA, and discusses successes in newborn screening
October is National Disability Employment Awareness Month, with an official theme of Increasing Access and Opportunity. Throughout the month, we will be posting stories about adults with SMA in the workforce and are pleased to share this story about AJ Brockman, 32, of Palm Beach Gardens, FL. AJ Brockman says he wears many hats in life. No
Community Spotlight: AJ Brockman of Brewhouse Gallery and Kelsey City Brewing Company Read More »
Cure SMA has published a paper, titled “Spinal Muscular Atrophy and COVID-19: Guidance and Resources for Providers,” in partnership with NeurologyLive. The article highlights findings from a recent survey conducted by Cure SMA to measure the impact of COVID-19 on the spinal muscular atrophy (SMA) patient and family community. As of June 1,
Cure SMA Publishes Paper in Partnership with NeurologyLive on Impact of COVID-19 Read More »
Novartis Gene Therapies today announced new interim data from the ongoing Phase 3 STR1VE-EU clinical trial for Zolgensma® (onasemnogene abeparvovec). The data demonstrates that patients with spinal muscular atrophy (SMA) Type 1 continued to experience significant therapeutic benefit, including event-free survival, rapid and sustained improvement in motor function, and motor milestone achievement, including
Novartis Presents New Zolgensma® Data Further Demonstrating Therapeutic Benefit Read More »
Genentech, a member of the Roche Group, today announced new 2-year data from Part 1 of the pivotal FIREFISH study of Evrysdi™ (risdiplam) in infants aged 2-7 months with symptomatic Type 1 spinal muscular atrophy (SMA). The 2-year results in infants treated with the therapeutic dose of Evrysdi (17/21) showed that they continued to improve
Genentech Presents New 2-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA Read More »
